Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$591.85
At close: May 28, 7:16 PM EDT
$597.10
5.250.89%
After Hours: 7:16 PM EDT
Comments
Loading...
Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga
Regeneron Pharmaceuticals Inc has a consensus price target of $920.21 based on the ratings of 29 analysts. The high is $1200 issued by TD Cowen on July 23, 2024. The low is $547 issued by B of A Securities on April 17, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Citigroup, and Guggenheim on May 27, 2025, May 14, 2025, and May 1, 2025, respectively. With an average price target of $817.67 between RBC Capital, Citigroup, and Guggenheim, there's an implied 36.94% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Citigroup
Guggenheim
Truist Securities
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Regeneron Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/27/2025 | Buy Now | 57.93% | RBC Capital | Brian Abrahams48% | $943 → $943 | Reiterates | Outperform → Outperform | Get Alert |
| 05/14/2025 | Buy Now | 17.23% | Citigroup | Geoff Meacham61% | $600 → $700 | Upgrade | Neutral → Buy | Get Alert |
| 05/01/2025 | Buy Now | 35.66% | Guggenheim | Yatin Suneja52% | $940 → $810 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 57.43% | Truist Securities | Srikripa Devarakonda43% | $975 → $940 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 34.65% | Goldman Sachs | Salveen Richter53% | $917 → $804 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 57.93% | RBC Capital | Brian Abrahams48% | $1051 → $943 | Maintains | Outperform | Get Alert |
| 04/30/2025 | Buy Now | 17.23% | Wells Fargo | Mohit Bansal67% | $750 → $700 | Maintains | Overweight | Get Alert |
| 04/30/2025 | Buy Now | 33.98% | BMO Capital | Evan David Seigerman44% | $865 → $800 | Maintains | Outperform | Get Alert |
| 04/30/2025 | Buy Now | 6.01% | UBS | Trung Huynh64% | $768 → $633 | Maintains | Neutral | Get Alert |
| 04/30/2025 | Buy Now | -1.69% | Baird | Brian Skorney57% | $652 → $587 | Maintains | Neutral | Get Alert |
| 04/29/2025 | Buy Now | 50.73% | Oppenheimer | Hartaj Singh45% | $925 → $900 | Maintains | Outperform | Get Alert |
| 04/25/2025 | Buy Now | 9.19% | Baird | Brian Skorney57% | $759 → $652 | Maintains | Neutral | Get Alert |
| 04/23/2025 | Buy Now | 63.29% | Truist Securities | Srikripa Devarakonda43% | $1004 → $975 | Maintains | Buy | Get Alert |
| 04/22/2025 | Buy Now | 42.35% | Canaccord Genuity | John Newman43% | $1152 → $850 | Maintains | Buy | Get Alert |
| 04/22/2025 | Buy Now | 16.4% | Cantor Fitzgerald | Carter Gould56% | → $695 | Assumes | → Overweight | Get Alert |
| 04/17/2025 | Buy Now | -8.39% | B of A Securities | Tim Anderson59% | $575 → $547 | Maintains | Underperform | Get Alert |
| 04/14/2025 | Buy Now | 53.58% | Goldman Sachs | Salveen Richter53% | $1019 → $917 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 81.04% | Morgan Stanley | Matthew Harrison61% | $1150 → $1081 | Maintains | Overweight | Get Alert |
| 04/03/2025 | Buy Now | 54.92% | Oppenheimer | Hartaj Singh45% | $950 → $925 | Maintains | Outperform | Get Alert |
| 03/31/2025 | Buy Now | 67.48% | JP Morgan | Chris Schott59% | $1100 → $1000 | Maintains | Overweight | Get Alert |
| 02/05/2025 | Buy Now | 27.11% | Baird | Brian Skorney57% | $940 → $759 | Maintains | Neutral | Get Alert |
| 02/05/2025 | Buy Now | 39.68% | Leerink Partners | David Risinger72% | $762 → $834 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/28/2025 | Buy Now | 25.61% | Citigroup | Geoff Meacham61% | $795 → $750 | Maintains | Neutral | Get Alert |
| 01/27/2025 | Buy Now | 69.65% | Piper Sandler | Christopher Raymond55% | $1195 → $1013 | Maintains | Overweight | Get Alert |
| 01/16/2025 | Buy Now | 23.6% | UBS | Trung Huynh64% | $1130 → $738 | Downgrade | Buy → Neutral | Get Alert |
| 01/14/2025 | Buy Now | 33.14% | Citigroup | Geoff Meacham61% | $895 → $795 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 59.1% | Oppenheimer | Hartaj Singh45% | $1000 → $950 | Maintains | Outperform | Get Alert |
| 01/10/2025 | Buy Now | 50.73% | Wells Fargo | Mohit Bansal67% | $1050 → $900 | Maintains | Overweight | Get Alert |
| 01/08/2025 | Buy Now | 68.15% | Truist Securities | Srikripa Devarakonda43% | $1126 → $1004 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 79.2% | Bernstein | William Pickering38% | $1110 → $1070 | Maintains | Outperform | Get Alert |
| 12/10/2024 | Buy Now | -5.38% | B of A Securities | Tim Anderson59% | → $565 | Reinstates | → Underperform | Get Alert |
| 11/15/2024 | Buy Now | 92.6% | Wolfe Research | Alexandria Hammond41% | → $1150 | Initiates | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | 49.89% | Citigroup | Geoff Meacham61% | → $895 | Initiates | → Neutral | Get Alert |
| 11/06/2024 | Buy Now | 67.48% | Oppenheimer | Hartaj Singh45% | $1150 → $1000 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 98.29% | Morgan Stanley | Matthew Harrison61% | $1235 → $1184 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 103.48% | RBC Capital | Brian Abrahams48% | $1260 → $1215 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 78.36% | Barclays | Carter Gould56% | $1080 → $1065 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 100.13% | Piper Sandler | Christopher Raymond55% | $1242 → $1195 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 99.3% | BMO Capital | Evan David Seigerman44% | $1300 → $1190 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 88.58% | Truist Securities | Srikripa Devarakonda43% | $1137 → $1126 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | 111.02% | RBC Capital | Brian Abrahams48% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | 96.78% | Evercore ISI Group | Cory Kasimov68% | $1250 → $1175 | Maintains | Outperform | Get Alert |
| 10/24/2024 | Buy Now | 92.6% | JP Morgan | Chris Schott59% | $1200 → $1150 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | 69.99% | Cantor Fitzgerald | Olivia Brayer52% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 10/23/2024 | Buy Now | 80.87% | Barclays | Carter Gould56% | $1220 → $1080 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 75.85% | Wells Fargo | Mohit Bansal67% | $1200 → $1050 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 111.02% | RBC Capital | Brian Abrahams48% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 90.42% | Truist Securities | Srikripa Devarakonda43% | $1200 → $1137 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | 111.02% | RBC Capital | Brian Abrahams48% | $1252 → $1260 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | 109.68% | RBC Capital | Brian Abrahams48% | $1282 → $1252 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | 117.72% | BMO Capital | Evan David Seigerman44% | $1300 → $1300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 100.97% | Truist Securities | Srikripa Devarakonda43% | $1200 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 80.37% | Leerink Partners | David Risinger72% | $1175 → $1077 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/23/2024 | Buy Now | 100.97% | Wells Fargo | Mohit Bansal67% | $1200 → $1200 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | 114.7% | RBC Capital | Brian Abrahams48% | $1282 → $1282 | Reiterates | Outperform → Outperform | Get Alert |
| 09/16/2024 | Buy Now | 69.99% | Cantor Fitzgerald | Olivia Brayer52% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | 69.99% | Cantor Fitzgerald | Olivia Brayer52% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | 114.7% | RBC Capital | Brian Abrahams48% | $1250 → $1282 | Maintains | Outperform | Get Alert |
| 09/05/2024 | Buy Now | 109.35% | RBC Capital | Brian Abrahams48% | $1250 → $1250 | Reiterates | Outperform → Outperform | Get Alert |
| 08/23/2024 | Buy Now | 108.01% | Piper Sandler | Christopher Raymond55% | $1166 → $1242 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 100.97% | JP Morgan | Chris Schott59% | $1150 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 107.67% | RBC Capital | Brian Abrahams48% | $1232 → $1240 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 117.72% | Guggenheim | Yatin Suneja52% | $1180 → $1300 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 100.97% | Wells Fargo | Mohit Bansal67% | $1125 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 104.32% | Barclays | Carter Gould56% | $1200 → $1220 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 100.97% | Truist Securities | Srikripa Devarakonda43% | $1135 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | 100.97% | TD Cowen | Tyler Van Buren45% | $1030 → $1200 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 67.48% | Cantor Fitzgerald | Olivia Brayer52% | $925 → $1000 | Maintains | Neutral | Get Alert |
| 07/19/2024 | Buy Now | 95.28% | Piper Sandler | Christopher Raymond55% | $1000 → $1166 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 97.62% | Guggenheim | Yatin Suneja52% | $1040 → $1180 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 97.96% | Morgan Stanley | Matthew Harrison61% | $1183 → $1182 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 100.97% | Barclays | Carter Gould56% | $1050 → $1200 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 92.93% | Canaccord Genuity | John Newman43% | $1152 → $1152 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 95.95% | Argus Research | Jasper Hellweg68% | $1060 → $1170 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 105.83% | RBC Capital | Brian Abrahams48% | $1229 → $1229 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 92.6% | JP Morgan | Chris Schott59% | $1050 → $1150 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | 105.83% | RBC Capital | Brian Abrahams48% | $1200 → $1229 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 100.97% | RBC Capital | Brian Abrahams48% | $1185 → $1200 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 92.6% | Evercore ISI Group | Cory Kasimov68% | → $1150 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 54.92% | Cantor Fitzgerald | Olivia Brayer52% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/24/2024 | Buy Now | 72.5% | TD Cowen | Tyler Van Buren45% | $1020 → $1030 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 84.06% | UBS | Colin Bristow38% | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 54.92% | Cantor Fitzgerald | Olivia Brayer52% | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | Buy Now | 54.92% | Cantor Fitzgerald | Louise Chen53% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | Buy Now | 20.58% | B of A Securities | Geoff Meacham61% | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | Buy Now | 99.13% | RBC Capital | Brian Abrahams48% | $1189 → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 90.09% | Truist Securities | Robyn Karnauskas54% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 90.09% | Truist Securities | Robyn Karnauskas54% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 86.74% | Morgan Stanley | Matthew Harrison61% | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 88.41% | Bernstein | William Pickering38% | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 88.41% | Bernstein | Aaron Gal53% | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 98.29% | RBC Capital | Brian Abrahams48% | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 54.92% | Cantor Fitzgerald | Olivia Brayer52% | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 85.9% | RBC Capital | Brian Abrahams48% | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 81.21% | BMO Capital | Evan David Seigerman44% | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 80.2% | RBC Capital | Brian Abrahams48% | $1076 → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | 70.83% | Barclays | Carter Gould56% | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | Buy Now | 80.2% | RBC Capital | Brian Abrahams48% | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | Buy Now | 42.35% | Cantor Fitzgerald | Olivia Brayer52% | $850 → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | Buy Now | 75.01% | Truist Securities | Robyn Karnauskas54% | → $1045 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN) stock?
The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by RBC Capital on May 27, 2025. The analyst firm set a price target for $943.00 expecting REGN to rise to within 12 months (a possible 57.93% upside). 78 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by RBC Capital, and Regeneron Pharmaceuticals reiterated their outperform rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on May 14, 2025 when Citigroup raised their price target to $700. Citigroup previously had a neutral for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a reiterated with a price target of $943.00 to $943.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $597.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
